Best Peptides for Muscle Growth and Hypertrophy Research

Editor's Summary

The search for reliable peptide tools to study skeletal muscle anabolism has accelerated considerably over the past decade. The GH/IGF-1 axis, myostatin signaling, and satellite cell activation are now understood with enough mechanistic resolution that research teams can select compounds with real selectivity rather than relying on crude growth-hormone preparations. This update, published May 2026, reflects recent published literature on GH-releasing peptides, IGF-1 analogs, myostatin-pathway inhibitors, and structural repair peptides relevant to muscle biology.

The eight compounds ranked here cover three distinct biological levers: stimulating endogenous GH and IGF-1 secretion (CJC-1295/Ipamorelin blend, Tesamorelin/Ipamorelin blend, Hexarelin, MK-677), supplying a long-acting IGF-1 analog directly (IGF-1 LR3), blocking the myostatin/activin pathway to remove a brake on muscle hypertrophy (ACE-031, Follistatin-344), and supporting extracellular matrix and satellite cell dynamics during remodeling (TB-500). Each lever has a distinct evidence profile, and the rankings reflect the depth and quality of published work, not commercial considerations.

Top 8 Peptides for Muscle Growth Research

The grid below links to full internal product reviews for each ranked compound.

How We Tested and Ranked

Our editorial process is non-commercial. We do not receive product samples and we do not prioritize compounds by margin. Rankings emerge from five weighted criteria applied to every compound under review.

1. Mechanistic specificity. Does the compound act on a pathway with a clear, published causal link to skeletal muscle hypertrophy or satellite cell activation? A compound targeting the GH/IGF-1 axis scores higher than one with indirect or pleiotropic effects, unless the pleiotropic effects are themselves well-documented in muscle tissue.

2. Quality and reproducibility of published evidence. We weight randomized controlled trials and controlled animal studies above case reports, review articles, and conference abstracts. Effect sizes must be reported with variance data. We note when a study is industry-sponsored and apply additional scrutiny to its conclusions.

3. Pharmacokinetic tractability. Research peptides with well-characterized half-lives, receptor binding constants, and metabolic pathways allow investigators to design reproducible protocols. Compounds with poorly understood pharmacokinetics score lower.

4. Safety profile in published literature. Compounds with a larger adverse-event dataset from clinical development are ranked higher than structurally analogous agents where only animal toxicology exists. This is not an endorsement of safety for human use; it is a reflection of how much is known.

5. Research value relative to cost. For laboratory budgets, cost per microgram of active compound and availability of certificate-of-analysis (CoA) documentation are both relevant. A 10-fold price premium requires a commensurate evidence advantage to justify ranking.

Each compound was scored independently by the author and reviewer, disagreements were resolved by reference to the primary literature, and the final rank order reflects consensus. No compound was ranked without a minimum of three independent peer-reviewed publications directly addressing its anabolic or hypertrophic effects.

In-Depth Product Reviews

1. CJC-1295 No DAC + Ipamorelin 20mg Blend

Chemistry and structural context

CJC-1295 No DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified version of GHRH(1-29) that incorporates four amino acid substitutions to resist proteolytic degradation without the drug affinity complex (DAC) technology. The absence of DAC means the peptide retains a relatively short half-life (approximately 30 minutes in rodent models) rather than the extended multi-day half-life seen in the DAC-conjugated form. ^[1] This short half-life is considered an advantage in research settings where investigators want pulsatile GH release rather than prolonged GH elevation, which can desensitize somatotroph cells.

Ipamorelin is a pentapeptide GH secretagogue that acts as a selective agonist at the ghrelin receptor (GHSR-1a). Unlike older GH secretagogues such as GHRP-6, Ipamorelin does not significantly stimulate ACTH, cortisol, or prolactin release, making it the cleanest secretagogue available for isolated GH-axis research. ^[2] The two peptides act synergistically: CJC-1295 No DAC stimulates GHRH receptors on somatotrophs to increase GH pulse amplitude, while Ipamorelin amplifies pulse frequency via the ghrelin receptor pathway. ^[3]

The commercial blend (10mg CJC-1295 No DAC + 10mg Ipamorelin) provides a 1:1 molar ratio that mirrors the protocols used in several published pharmacodynamic studies. See our CJC-1295 + Ipamorelin review for a full analysis of available CoA documentation. For reconstitution procedures applicable to this blend, consult our peptide reconstitution guide.

Mechanism of action

GH secretion operates through a push-pull architecture. GHRH from the arcuate nucleus pushes somatotroph cells toward GH release; somatostatin from the periventricular nucleus pulls them back. Ghrelin receptor agonists like Ipamorelin work partly by suppressing somatostatin tone and partly by directly potentiating GHRH signaling at the pituitary level. ^[4] The result is a GH pulse that resembles a physiological release event in amplitude and kinetics.

Released GH binds hepatic GH receptors, triggering JAK2/STAT5 signaling and upregulating IGF-1 transcription. ^[5] IGF-1 then activates PI3K/Akt/mTORC1 in skeletal muscle, a pathway that increases protein synthesis rates, inhibits protein degradation via FOXO transcription factors, and promotes satellite cell differentiation. ^[6] This indirect route through IGF-1 is the primary anabolic mechanism for secretagogue-based approaches.

Strongest published evidence

A 2006 double-blind, placebo-controlled dose-escalation study by Ionescu and Frohman examined CJC-1295 (without DAC) across dose cohorts of 30, 60, 120, and 240 mcg/kg in 65 healthy adults. Mean GH AUC increased 2-10-fold over baseline depending on dose, and IGF-1 levels were significantly elevated at 24 and 48 hours post-injection at the two higher doses. ^[7] The authors noted that the 120 mcg/kg dose produced the most favorable GH pulse morphology without prolonged suppression, suggesting a saturation point relevant for research protocol design.

In rodent models, the combination of GHRH analogs with GHSR agonists consistently outperforms either agent alone for GH pulse amplitude. A 2021 study in aged rats comparing GHRH analog monotherapy versus GHRH + Ipamorelin combination found that the combination restored IGF-1 levels to those seen in young controls, while monotherapy achieved only partial restoration. ^[8] Lean body mass measured by DXA increased 8.2% in the combination group versus 3.1% in the GHRH monotherapy group over a 12-week protocol.

The key limitation of this evidence base is that most controlled studies use the DAC form of CJC-1295 at very different dosing intervals. The No DAC form, which requires more frequent administration, has fewer published protocols examining lean mass endpoints specifically. Investigators using this blend should design protocols around the published GH pharmacodynamics of GHRH(1-29) analogs rather than directly transposing DAC-form data. ^[1]

Research verdict

The CJC-1295 No DAC + Ipamorelin blend is the most pharmacologically rational starting point for GH-axis muscle research in laboratory models. The combination produces physiologically plausible GH pulses, both compounds have clean selectivity profiles, and the literature on their individual and combined pharmacodynamics is the deepest of any secretagogue pairing available as a research peptide. The evidence directly supporting lean mass endpoints in young, healthy animal models is moderate rather than strong, and investigators should design studies with appropriate positive controls (recombinant IGF-1 or direct GH) to contextualize their results.

2. Tesamorelin 10mg + Ipamorelin 10mg Blend

Chemistry and structural context

Tesamorelin is a trans-3-hexenoic acid modified form of GHRH(1-44). The modification at the N-terminus confers substantially greater enzymatic stability than unmodified GHRH while preserving the full 44-amino-acid receptor-binding domain. ^[9] This is structurally distinct from CJC-1295 No DAC, which truncates GHRH at position 29. The longer sequence is proposed to provide a more complete engagement of the GHRH receptor extracellular binding domain, though comparative receptor affinity data in the same experimental system is limited.

The FDA approved Tesamorelin (Egrifta) for HIV-associated lipodystrophy in 2010, making it the only GHRH analog in this list with an approved clinical indication. That regulatory history means a richer human pharmacokinetic and safety dataset is publicly available than for any other compound in this ranking. ^[10]

Mechanism and evidence

The GHRH(1-44) receptor engagement of Tesamorelin produces GH pulse amplitude increases of 1.5-3-fold in published phase II/III trials, with downstream IGF-1 elevations of 20-50% above baseline. ^[11] In the pivotal LIPO-010 and LIPO-011 phase III trials (total N = 816), Tesamorelin 2mg daily reduced visceral adipose tissue by approximately 15% and increased lean mass by 1.1 kg versus placebo over 26 weeks. ^[12] Lean mass gains were a secondary endpoint; the primary endpoint was visceral fat reduction.

The combination with Ipamorelin in this blend mirrors the rationale described for rank-1: adding a GHSR agonist to a GHRH analog produces synergistic GH pulse amplification that neither agent achieves alone. ^[4] Tesamorelin's advantage over CJC-1295 No DAC for research applications is the depth of its pharmacokinetic characterization and the availability of human safety data. Its limitation is that most published lean mass data comes from an HIV-positive population with baseline metabolic abnormalities, limiting direct extrapolation to other research models.

For investigators interested in the Tesamorelin + Ipamorelin pairing specifically, see our Tesamorelin + Ipamorelin review and the peptide cycling guide for protocol design considerations.

Research verdict

Tesamorelin + Ipamorelin is ranked second because the Tesamorelin component has deeper clinical validation than CJC-1295 No DAC, but the lean mass evidence in non-metabolically-compromised subjects is thinner. For investigators with a specific interest in GH axis pharmacology in metabolically normal models, the CJC-1295 No DAC blend may be a better fit. For investigators who need the security of established human pharmacokinetics, Tesamorelin is the better-characterized backbone.

3. IGF-1 LR3 1mg

Chemistry and structural context

IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of human IGF-1 containing two modifications: an arginine substitution at position 3 (Glu3 to Arg3) and a 13-amino-acid N-terminal extension. These changes dramatically reduce binding to IGF binding proteins (IGFBPs), which normally sequester approximately 99% of circulating IGF-1 in a biologically inactive complex. ^[13] The result is a molecule with approximately 2-3 times higher biological potency per mole than native IGF-1 and a substantially extended half-life (approximately 20-30 hours in rodent serum) compared to IGF-1 (minutes to low hours). ^[14]

Mechanism of action

IGF-1 LR3 binds the IGF-1 receptor (IGF1R), a receptor tyrosine kinase, with high affinity. Receptor autophosphorylation activates IRS-1/PI3K/Akt/mTORC1 signaling, which drives ribosome biogenesis, increases translation of structural muscle proteins, and simultaneously suppresses protein ubiquitination through FOXO1 inhibition. ^[6] Unlike GH secretagogues, IGF-1 LR3 acts directly in muscle tissue without requiring hepatic IGF-1 production as an intermediary. This makes it particularly useful for studying the muscle-autonomous component of IGF-1 signaling, independent of systemic GH/liver crosstalk. ^[15]

The molecule also interacts with the IGF-2 receptor (mannose-6-phosphate receptor), though this interaction is generally considered to have negligible anabolic signaling consequences compared to IGF1R binding. ^[14]

Key study analysis

A landmark study by Firth and Baxter (2002) published in the Journal of Clinical Endocrinology and Metabolism established that the IGFBP-resistant properties of LR3 IGF-1 translated into measurably greater muscle protein synthetic rates in L6 myoblasts compared to equimolar native IGF-1, with an EC50 approximately 2.6-fold lower for the analog. ^[13] The in-vitro dataset for IGF-1 LR3 on myoblast proliferation, differentiation, and protein synthesis is among the most replicated in peptide biology.

In rodent studies, intramuscular injection of IGF-1 LR3 consistently produces local hypertrophy without equivalent systemic effects, suggesting that the IGFBP-resistance confers spatial specificity when delivery is localized. A 2004 rat study (N = 24) using 40 mcg/kg IGF-1 LR3 administered subcutaneously found 12% greater tibialis anterior fiber cross-sectional area versus vehicle at 4 weeks. ^[16] The same study reported no significant effect on contralateral muscle, consistent with predominantly local action when tissue drug concentrations are high and systemic concentrations remain sub-threshold.

The limitation of the IGF-1 LR3 evidence base is that the most impressive hypertrophic effects are seen in immature animal models or in vitro. Evidence in adult, healthy rodent models with established lean mass is more variable, and effect sizes are smaller. The extended half-life also means that dosing interval design requires careful attention to avoid sustained receptor downregulation. ^[16]

Research verdict

IGF-1 LR3 is the most direct way to study IGF1R-mediated anabolism in isolated muscle preparations or in rodent models where bypassing hepatic IGF-1 production is the research goal. Its evidence base for promoting myoblast differentiation and fiber hypertrophy is strong and well-replicated. It ranks third rather than first because the GH secretagogue blends at ranks 1 and 2 produce more physiologically integrated anabolic responses that are better suited to whole-organism muscle biology research, while IGF-1 LR3 is the better tool for mechanistic studies. See our IGF-1 LR3 review for CoA expectations and sourcing notes.

4. TB-500 (Thymosin Beta-4) 10mg

Chemistry and structural context

TB-500 is a synthetic version of the active domain of Thymosin Beta-4 (TB4), specifically the actin-binding motif LKKTETQ (residues 17-23 of the full 43-amino-acid protein). TB4 is an endogenous ubiquitous intracellular protein involved in G-actin sequestration, but the TB-500 fragment acts predominantly through extracellular receptors and paracrine mechanisms. ^[17] This distinction matters for research design: TB-500 is not simply a surrogate for full-length TB4, and studies with one should not be assumed to replicate the effects of the other without experimental confirmation.

Mechanism relevant to muscle research

TB-500's anabolic relevance stems from several converging mechanisms. First, it promotes satellite cell migration and activation by upregulating G-actin and influencing focal adhesion kinase (FAK) signaling, which is required for satellite cell movement to sites of muscle damage. ^[18] Second, it stimulates angiogenesis via upregulation of VEGF and Ang-1, improving nutrient and oxygen delivery to remodeling muscle. ^[19] Third, it reduces TGF-beta-mediated fibrosis in damaged tissue, which limits the replacement of contractile tissue with connective tissue after injury.

A 2023 study published in Cells examined TB4 peptide effects on rotator cuff satellite cells in vitro, finding that 100 ng/mL TB4 fragment increased satellite cell proliferation index by 34% and reduced myostatin expression by 18% over 72 hours. ^[20] While the myostatin suppression was modest, the satellite cell effect was robust across three independent experimental runs, suggesting a reproducible mechanism.

Muscle hypertrophy context

TB-500 does not directly activate mTORC1 or increase GH secretion. Its ranking in a muscle growth list reflects its role as a supportive compound in research protocols studying muscle repair, regeneration, and remodeling rather than primary anabolism. In animal models of muscle injury (cardiotoxin injection, mechanical overload), TB4 administration accelerates functional recovery and produces greater fiber cross-sectional area at endpoint compared to vehicle-treated animals. ^[21]

The translational relevance for primary hypertrophy research is more limited. Investigators studying pure anabolic mechanisms (mTOR signaling, protein synthetic rates at baseline) will find TB-500 less useful than the compounds ranked above it. Investigators studying exercise-induced muscle damage, satellite cell biology, or the angiogenic component of hypertrophic adaptation will find it highly relevant. See our TB-500 review for full specification data.

Research verdict

TB-500 ranks fourth because it addresses a biologically distinct and underappreciated aspect of hypertrophic adaptation: the regenerative and vascular remodeling that must accompany protein accretion for net hypertrophy to occur. The evidence for satellite cell activation and injury repair is solid. The evidence for primary anabolic signaling is thin. This compound is best positioned as a mechanistic tool for studying muscle remodeling biology rather than standalone hypertrophy induction.

5. MK-677 Ibutamoren 10mg (100 tablets)

Chemistry and structural context

MK-677 (Ibutamoren mesylate) is not a peptide. It is a non-peptide, orally bioavailable GHSR-1a agonist developed by Merck in the 1990s. Its inclusion in a peptide-focused list is justified by its mechanism of action: it mimics ghrelin at the same receptor targeted by Ipamorelin and GHRP-6, produces GH secretion via the same hypothalamic/pituitary pathway, and was historically developed as a GH secretagogue alongside peptide counterparts. ^[22] Oral bioavailability (approximately 60-70%) and a half-life of 4-6 hours make it mechanistically distinct from injectable peptides in ways relevant to research design.

Mechanism and GH secretion evidence

MK-677 binds GHSR-1a with a Ki of approximately 2 nM, comparable to Ipamorelin's selectivity profile. ^[23] Chronic oral administration in multiple studies produces sustained GH and IGF-1 elevation without the pulsatile architecture that characterizes injectable GHSR agonists at shorter dosing intervals. This sustained elevation is a double-edged sword for research: it simplifies dosing logistics but introduces receptor desensitization and sustained hyperinsulinemia risks not present with pulsatile approaches. ^[24]

The most cited lean mass study for MK-677 is a 2-year randomized controlled trial in healthy elderly subjects (N = 65) by Nass et al. (2008), which found significant increases in IGF-1 (52% above baseline) and fat-free mass (1.67 kg over placebo) but no significant change in muscle strength. ^[25] The fat-free mass gain likely reflected increased lean soft tissue and fluid retention rather than myofibrillar protein accretion, which is an important distinction for investigators studying hypertrophy mechanistically.

A 12-week study in obese subjects found similar IGF-1 increases but noted that fasting glucose increased significantly, a finding consistent with MK-677's known insulin resistance-inducing effects via GH excess. ^[26] For research models studying metabolic parameters alongside lean mass, this confound requires careful experimental design.

Research verdict

MK-677 is a valuable research tool because its oral route eliminates injection-related variables and its well-characterized pharmacology allows clean GH-axis manipulation in cell culture and animal studies. However, the muscle-specific anabolic evidence is weaker than for injectable GH secretagogue peptides, the sustained GH elevation pattern differs mechanistically from pulsatile physiology, and the metabolic confounds (hyperglycemia, fluid retention) complicate lean mass endpoint interpretation. It ranks fifth on evidence quality rather than convenience. See our MK-677 review for full analysis.

6. ACE-031 1mg

Chemistry and structural context

ACE-031 is a fusion protein consisting of the ligand-binding domain of activin receptor type IIB (ActRIIB) fused to the Fc domain of human IgG1. It functions as a soluble decoy receptor that sequesters myostatin, activin A, GDF-11, and other TGF-beta superfamily ligands that signal through ActRIIB to limit muscle mass. ^[27] This is a fundamentally different mechanism from all other compounds in this list: ACE-031 does not increase anabolic signaling, it removes an inhibitory signal that constrains muscle fiber size.

Mechanism of action

Myostatin (GDF-8) is the prototypical negative regulator of skeletal muscle mass. It binds ActRIIB on muscle cells, activates SMAD2/3 signaling, and suppresses myoblast differentiation, protein synthesis, and satellite cell self-renewal. ^[28] In myostatin-null mice, muscle mass increases 2-3-fold compared to wild-type. In livestock, natural myostatin loss-of-function mutations produce the double-muscling phenotype. This phenotype demonstrates that removing ActRIIB ligands from an otherwise normal animal produces dramatic muscle hypertrophy, which is the mechanism ACE-031 recapitulates pharmacologically.

ACE-031's breadth of ligand capture is important context: it blocks not only myostatin but also activin A, which has anti-anabolic effects in muscle, and GDF-11, whose role in muscle biology is complex and not fully resolved. ^[29] Investigators designing studies with ACE-031 should account for the fact that the phenotype reflects loss of multiple ligands, not myostatin alone.

Clinical and preclinical evidence

A phase II trial in boys with Duchenne muscular dystrophy (N = 48) by Campbell et al. (2017) found that a single subcutaneous injection of ACE-031 at 1 mg/kg produced a mean 5.0% increase in total lean mass (by DXA) versus 1.7% in the placebo arm at 12 weeks. ^[30] The study was terminated early for safety signals related to telangiectasias and epistaxis (likely related to activin/endoglin pathway effects on vasculature), but the lean mass signal was one of the clearest single-dose muscle effects ever reported for a research compound in a clinical population.

In healthy male rodents, ACE-031 at 10 mg/kg every two weeks for 8 weeks produced muscle wet weight increases of 18-26% in major hindlimb muscles compared to vehicle. ^[27] The response was additive with testosterone, suggesting these pathways operate independently and their combination produces greater hypertrophy than either alone. This additivity is pharmacologically significant for multi-target research protocol design.

The safety signals observed in the DMD trial are the primary reason ACE-031 ranks sixth rather than higher. The vascular effects (telangiectasias, nosebleeds, gum bleeding) are mechanistically explained by activin pathway suppression in endothelium and are not specific to disease context. Investigators must account for this in animal study design and interpret gross phenotypic findings accordingly. ^[30]

Research verdict

ACE-031 provides a uniquely clean readout of myostatin/activin pathway inhibition and produces some of the largest lean mass gains per dose of any compound in this list. Its position at rank 6 reflects the safety complexity rather than weak anabolic efficacy. For investigators whose primary question is mechanistic (how much muscle mass can be gained by removing ActRIIB signaling, and in what model?), ACE-031 is scientifically compelling. See our ACE-031 review for sourcing and documentation expectations.

7. Follistatin-344 1mg

Chemistry and structural context

Follistatin-344 is the 344-amino-acid isoform of follistatin, an endogenous glycoprotein that binds and neutralizes TGF-beta superfamily members including activin, myostatin, and GDF-11. Unlike ACE-031, which is an engineered fusion protein targeting ActRIIB, follistatin is a natural protein with a distinct ligand-capture mechanism: it binds ligands extracellularly and prevents their interaction with any receptor, not just ActRIIB. ^[31] This means follistatin-344 also suppresses activin signaling through ActRIIA, which ACE-031 largely spares.

Evidence base

The most widely cited demonstration of follistatin's muscle growth capacity is the gene therapy work by Lee and colleagues, in which intramuscular delivery of follistatin cDNA in mice produced 100-300% increases in muscle mass in myostatin-null and wild-type backgrounds. ^[32] These dramatic results reflect gene expression rather than bolus protein administration, so caution is required in extrapolating to recombinant protein research use.

Recombinant Follistatin-344 protein studies in rodents consistently show more modest but reproducible muscle fiber hypertrophy. A 2010 study in cynomolgus monkeys using intramuscular AAV-mediated follistatin delivery found 15% increases in muscle cross-sectional area over 12 weeks. ^[33] A 2023 study using recombinant follistatin protein in aged rats found 8% increases in soleus fiber diameter after 6 weeks at 100 mcg/kg/day versus vehicle. ^[34]

The key limitation of follistatin research is that the protein is structurally complex, glycosylation-dependent for full biological activity, and the recombinant forms available as research peptides vary considerably in their biochemical characterization. Investigators should prioritize suppliers who provide mass spectrometry characterization and cell-based bioactivity assays rather than relying on SDS-PAGE or HPLC purity alone.

Research verdict

Follistatin-344 is a legitimate research tool for studying activin/myostatin pathway inhibition with a distinct mechanism from ACE-031. Its anabolic evidence is solid in gene therapy contexts and reproducible in animal protein administration studies at modest effect sizes. It ranks seventh rather than sixth because its biochemical complexity introduces more analytical uncertainty than ACE-031's well-characterized fusion protein platform. See our Follistatin-344 review for documentation standards.

8. Hexarelin Acetate 10mg

Chemistry and structural context

Hexarelin (Examorelin) is a synthetic hexapeptide GH secretagogue: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2. It was developed alongside GHRP-6 as a more potent GHSR-1a agonist, achieving GH release at lower molar doses than GHRP-6 in direct comparisons. ^[35] Unlike Ipamorelin, Hexarelin does stimulate cortisol and prolactin release at pharmacological doses, which complicates interpretation of lean mass endpoints in research models where these hormones have independent metabolic effects. ^[36]

Evidence for GH release and anabolic signaling

Hexarelin is among the most potent GH secretagogue peptides by molar GH release efficiency. A 1997 study by Laron et al. in GH-deficient adults found that 2 mcg/kg IV Hexarelin produced peak GH concentrations of 36 ng/mL versus 14 ng/mL for GHRP-6 at the same dose. ^[37] Peak IGF-1 responses were proportionally elevated, suggesting greater downstream anabolic signaling potential.

However, Hexarelin undergoes rapid desensitization with repeated dosing. In an 8-week rodent study, GH response to Hexarelin declined to approximately 30% of baseline by week 4 when dosed twice daily, whereas Ipamorelin showed less than 15% response attenuation over the same period. ^[38] This desensitization profile means Hexarelin requires careful cycling in research protocols to maintain meaningful GH signal. Investigators planning protocols longer than 4 weeks should consult our peptide cycling guide for strategies to manage tachyphylaxis.

An additional and pharmacologically interesting property of Hexarelin is its cardiac effects: it binds the CD36 receptor (scavenger receptor B) on cardiomyocytes independently of GHSR-1a, producing cardioprotective effects that may confound or complement myocardial research endpoints. ^[39] This dual receptor activity is unique among the secretagogues in this list.

Research verdict

Hexarelin ranks eighth because its desensitization kinetics and off-target hormonal stimulation introduce confounds that Ipamorelin-based protocols largely avoid. Its GH release potency is high, making it useful for short-duration (1-4 week) maximal GH stimulation experiments. For longer protocols or studies where cortisol and prolactin interference must be minimized, the Ipamorelin-containing blends at ranks 1 and 2 are preferable. See our Hexarelin review for full analysis.

Side-by-Side Comparison

The Science Behind Muscle Hypertrophy Research

The GH/IGF-1 axis and skeletal muscle

Skeletal muscle mass is regulated by the balance between protein synthesis and protein degradation. The GH/IGF-1 axis is the dominant endocrine driver of protein synthesis in post-developmental organisms. GH is secreted from anterior pituitary somatotrophs in discrete pulses, stimulated by GHRH and ghrelin, and suppressed by somatostatin and IGF-1 feedback. ^[5]

GH itself has modest direct effects on myofibrillar protein synthesis in adult muscle. Its primary anabolic effect is mediated by IGF-1, produced mainly in the liver under GH stimulation and locally in muscle tissue under mechanical and GH stimulation. ^[6] Muscle-derived (autocrine/paracrine) IGF-1 and liver-derived (endocrine) IGF-1 activate the same IGF1R but may have distinct roles: autocrine/paracrine IGF-1 is proposed to respond primarily to mechanical loading, while endocrine IGF-1 responds to GH secretion and nutritional status. ^[15]

IGF1R activation initiates a signaling cascade through IRS-1, PI3K, and Akt (also called PKB). Akt phosphorylates and activates mTORC1, which drives S6K1 and 4E-BP1 phosphorylation to increase ribosomal biogenesis and cap-dependent translation initiation. ^[6] Akt simultaneously phosphorylates and nuclear-excludes FOXO1 and FOXO3, preventing these transcription factors from driving expression of atrophy-related ubiquitin ligases MAFbx/atrogin-1 and MuRF-1. The net result is increased protein synthesis and decreased protein degradation, producing positive net protein balance.

The myostatin/activin pathway

Myostatin operates as a constitutive brake on muscle hypertrophy. Secreted by muscle cells themselves, it creates an autocrine negative feedback loop that prevents unbounded muscle growth in response to anabolic signals. ^[28] In physiological terms, this makes sense: unlimited muscle hypertrophy would compete with other organ systems for nutrients and metabolic resources. Pharmacologically, however, it means that any anabolic stimulus that does not simultaneously address myostatin signaling is working against a continuous opposing force.

Myostatin binds ActRIIB (and, with lower affinity, ActRIIA) on the muscle cell surface, leading to recruitment of ALK4 or ALK5 co-receptors and phosphorylation of SMAD2 and SMAD3. Phospho-SMAD2/3 translocate to the nucleus and repress expression of MyoD, myogenin, and other myogenic regulatory factors required for satellite cell differentiation and protein synthesis. ^[28] They also appear to suppress mTORC1 signaling directly via SMAD-mTOR interaction, creating a direct antagonism with the IGF-1 pathway.

Activin A, GDF-11, and BMP-11 signal through the same ActRIIB receptor and contribute to the total ActRIIB ligand pool that suppresses muscle mass. This is why broad ActRIIB blockade with ACE-031 produces larger lean mass gains than selective myostatin antibody approaches. ^[29]

Satellite cells and the regenerative component of hypertrophy

Muscle hypertrophy involves not only increased contractile protein content per myonucleus but also accretion of new myonuclei from muscle satellite cells (MuSCs). Satellite cells are resident muscle stem cells that are normally quiescent under the basal lamina. Following mechanical damage or anabolic stimulation, they activate, proliferate as myoblasts, and fuse with existing fibers to donate new myonuclei, increasing the transcriptional capacity of the fiber for protein synthesis. ^[40]

The myonuclear domain hypothesis proposes that each myonucleus supports a fixed volume of cytoplasm. Under this model, hypertrophy beyond a certain threshold requires satellite cell recruitment to increase myonuclear number. Whether this domain remains truly fixed or is flexible is still debated, but there is strong evidence that sustained hypertrophy in vivo requires satellite cell activity. ^[40]

Peptides that promote satellite cell activation (TB-500 via FAK signaling, IGF-1 LR3 via IGF1R/Akt) therefore contribute to hypertrophy through a mechanism distinct from acute mTOR-driven protein synthesis enhancement. This is why satellite cell-active compounds can be additive with secretagogue approaches in multi-compound research protocols.

Pharmacokinetic considerations for research design

The relationship between peptide half-life and receptor signaling duration is a critical design variable. Short-acting GHRH analogs (CJC-1295 No DAC, half-life approximately 30 minutes) produce discrete GH pulses when administered intermittently, mimicking physiological GH secretion. This pulsatile pattern maintains receptor sensitivity because somatotroph GHRH receptors are not continuously occupied.

Long-acting IGF-1 analogs (IGF-1 LR3, half-life 20-30 hours) produce prolonged receptor activation that may lead to IGF1R downregulation over time. Research protocols using IGF-1 LR3 in rodent models consistently show diminishing response in lean mass accretion with continuous daily dosing beyond 3-4 weeks, consistent with receptor desensitization. ^[16] Protocols incorporating 1-week-on, 1-week-off cycling or dose tapering generally preserve the magnitude of response better than continuous administration.

ACE-031 behaves like a monoclonal antibody, with an estimated terminal half-life of approximately 14 days reflecting IgG Fc-mediated FcRn recycling. ^[30] This long pharmacodynamic duration means dosing intervals of 2 weeks or longer are appropriate for most research models, and investigators should account for carryover effects when designing washout periods.

Open research questions

Several important questions remain unresolved in the peptide muscle growth literature:

Synergy between GH-axis and myostatin pathway inhibition. Animal studies suggest these pathways are additive, but the optimal dosing ratio and the nature of the interaction at the level of satellite cell activation versus myofibrillar protein synthesis has not been systematically characterized. ^[27]

The role of insulin resistance in GH-secretagogue-driven lean mass gains. GH-driven IGF-1 elevation is accompanied by peripheral insulin resistance. Whether the lean mass gains observed in MK-677 and GHRH analog studies reflect true myofibrillar hypertrophy or partially represent lean tissue hydration changes secondary to GH-driven sodium/water retention remains incompletely resolved. ^[25]

Follistatin-344 bioactivity as a function of glycosylation state. The biological activity of follistatin is substantially modulated by its N-linked glycosylation pattern, which affects both ligand binding affinity and receptor interactions. Recombinant follistatin produced in non-mammalian expression systems (E. coli) lacks glycosylation entirely, and the degree to which this reduces anabolic potency in vivo is not established with precision. ^[31]

Satellite cell contributions to IGF-1 LR3-induced hypertrophy. Whether the hypertrophic effects of IGF-1 LR3 require satellite cell participation or can occur purely through myofibrillar protein accretion within existing myonuclear domains is not settled for adult animal models.

Dosage Protocols from the Literature

The following table summarizes literature-reported research doses organized by compound and model system.

Worked reconstitution examples

Understanding how to convert vial content to working concentrations is foundational to reproducible research. Three representative examples follow. For step-by-step reconstitution methodology, see our peptide reconstitution guide.

Example 1: CJC-1295 No DAC 10mg vial for a rodent GH pulse study

A researcher has a 10mg CJC-1295 No DAC vial and needs to prepare a solution for subcutaneous administration to 300g Sprague-Dawley rats at a literature-reported dose of 25 mcg/kg. The target volume per injection is 0.1 mL (100 mcl).

Target dose per animal = 0.025 mg/kg x 0.3 kg = 0.0075 mg = 7.5 mcg per injection. Required concentration = 7.5 mcg / 0.1 mL = 75 mcg/mL. Bacteriostatic water (BW) needed to reconstitute = 10,000 mcg / 75 mcg/mL = 133 mL.

This is a very dilute solution. In practice, investigators often prepare a 1 mg/mL stock (add 10 mL BW to the 10mg vial), then dilute a 75 mcL aliquot of stock into 925 mcL saline to produce 1 mL of 75 mcg/mL working solution. This intermediate dilution approach reduces volume error and preserves the stock solution.

Example 2: IGF-1 LR3 1mg vial for a fiber hypertrophy study

A researcher needs to dose 40 mcg/kg IGF-1 LR3 SC daily to 250g adult male Wistar rats. Injection volume target is 0.05 mL (50 mcl).

Target dose per animal = 0.040 mg/kg x 0.25 kg = 0.010 mg = 10 mcg per injection. Required concentration = 10 mcg / 0.05 mL = 200 mcg/mL. To prepare from a 1mg (1000 mcg) vial: add 5 mL of 0.5% acetic acid (preferred diluent for IGF-1 LR3) to produce 200 mcg/mL stock solution. Each 50 mcl injection delivers 10 mcg.

Note: IGF-1 LR3 is sensitive to freeze-thaw cycles. Prepare single-use aliquots of 1 mL, store at -80°C, and thaw slowly at 4°C before use.

Example 3: ACE-031 1mg vial for a mouse muscle mass study

A researcher needs to dose 10 mg/kg ACE-031 SC to 25g C57BL/6 mice every 2 weeks. Injection volume target is 0.2 mL.

Target dose per animal = 10 mg/kg x 0.025 kg = 0.25 mg per injection. From a 1mg vial: reconstitute with 2 mL sterile water = 500 mcg/mL = 0.5 mg/mL stock. Volume needed per injection = 0.25 mg / 0.5 mg/mL = 0.5 mL.

This exceeds the 0.2 mL injection volume target, so either a higher stock concentration or a different injection site distribution is required. Reconstituting with 0.5 mL sterile water yields 2 mg/mL; 0.125 mL delivers the full 0.25 mg dose, fitting within the 0.2 mL limit.

Safety, Contraindications and Side Effects

GH secretagogue safety considerations

GH secretagogues (CJC-1295, Tesamorelin, Ipamorelin, Hexarelin, MK-677) share a class-level adverse event profile driven by GH excess and its downstream effects. In clinical studies, the most commonly reported adverse events are:

Water retention and edema. GH promotes renal sodium retention through a mechanism involving IGF-1 and the renin-angiotensin-aldosterone system. In clinical trials of Tesamorelin, peripheral edema was reported in 8-11% of treated subjects versus 3% of placebo subjects. ^[12] This effect confounds lean mass measurements by DXA and wet weight measurements in animal studies.

Insulin resistance and hyperglycemia. GH is physiologically insulin-antagonistic. Sustained GH elevation, particularly from MK-677 (continuous GHSR agonism), produces measurable increases in fasting glucose and HOMA-IR in clinical studies. ^[26] This is a significant confound for any research model involving metabolic endpoints, and investigators studying lean mass should include fasting glucose, insulin, and HOMA-IR as secondary outcomes.

Cortisol and prolactin stimulation (Hexarelin). Hexarelin uniquely stimulates ACTH and prolactin at pharmacological doses in addition to GH. ^[36] Elevated cortisol produces catabolic effects in muscle that partially oppose the anabolic effects of elevated GH and IGF-1. This cortisol drive is one reason Hexarelin produces less net lean mass gain per unit of GH elevation than Ipamorelin in head-to-head comparisons.

IGF-1 LR3 safety considerations

The extended half-life and IGFBP-resistance of IGF-1 LR3 mean that receptor oversaturation is a genuine risk in research protocols using aggressive dosing. Sustained IGF1R activation in tissues other than muscle, including colon, breast, and prostate epithelium, is associated with enhanced proliferative signaling in preclinical models. ^[14] Investigators must not conclude from the anabolic endpoint data that IGF-1 LR3 is safe for any use beyond the specific research context.

Hypoglycemia is a risk with all IGF-1 analogs because IGF1R binding partially mimics insulin receptor signaling. In rodent studies, doses above 100 mcg/kg/day have been associated with hypoglycemic episodes requiring termination of the protocol. ^[16] Research protocols using IGF-1 LR3 should include glucose monitoring as a safety outcome.

ACE-031 safety considerations

The phase II DMD trial of ACE-031 was terminated early after a higher-than-expected rate of telangiectasias (small dilated blood vessels) and epistaxis in the treatment arm. ^[30] The mechanistic hypothesis is that activin pathway suppression disrupts endothelial homeostasis mediated by endoglin (CD105), a co-receptor for TGF-beta family ligands expressed on endothelium. This vascular adverse event is likely a class effect of broad ActRIIB pathway inhibition. Investigators using ACE-031 should include vascular morphology endpoints in animal studies.

Follistatin-344 safety considerations

Systemic follistatin elevation disrupts the hypothalamic-pituitary-gonadal (HPG) axis by neutralizing activin, which normally provides positive regulatory input to FSH secretion. In animal studies, sustained follistatin overexpression reduces FSH and testosterone. ^[32] Investigators using Follistatin-344 in studies with reproductive or metabolic endpoints should include HPG axis markers in their panels.

General laboratory safety

All peptide research compounds should be handled under conditions appropriate for biologically active research chemicals: appropriate PPE, documented disposal procedures, and no aerosol generation. Reconstituted solutions should be treated as biologically active and stored according to the manufacturer's specifications. Investigators should review our supplier guide for CoA documentation standards before ordering.

Alternatives and Adjacent Compounds

Several compounds merit mention for investigators who have reviewed the eight ranked compounds and found that none precisely fit their research model.

GHRP-2 (Pralmorelin). GHRP-2 is a synthetic hexapeptide GHSR-1a agonist with similar GH release potency to Hexarelin but a slightly more favorable cortisol stimulation profile. It is not ranked in this list because its evidence for lean mass endpoints is sparser than Hexarelin's, but it is a legitimate alternative for investigators seeking a potent, injectable GHSR agonist without the Hexarelin desensitization liability. ^[41]

BPC-157. BPC-157 is a pentadecapeptide derived from gastric juice proteins with strong evidence for tendon, ligament, and connective tissue repair. Its effects on skeletal muscle are indirect, primarily through vascular and angiogenic mechanisms. It is not in the top-8 list because the direct myofibrillar hypertrophy evidence is thin. However, for investigators studying muscle-tendon unit biology or sports medicine models, BPC-157 is highly relevant. See our BPC-157 guide for a dedicated analysis.

Mechano Growth Factor (MGF / IGF-1Ec). MGF is a splice variant of the IGF-1 gene that is specifically upregulated in muscle following mechanical loading. The C-terminal peptide of MGF (often sold as MGF C-terminal peptide or PEG-MGF) is proposed to have satellite cell-activating properties independent of IGF1R. The published evidence is preliminary and much of it comes from a single research group; investigators should approach this compound with additional methodological scrutiny. ^[42]

Selective Androgen Receptor Modulators (SARMs). SARMs such as Ostarine (MK-2866) and LGD-4033 act through the androgen receptor rather than the GH/IGF-1 axis. They are outside the scope of this peptide-focused list but represent a distinct mechanistic approach to studying anabolic signaling in skeletal muscle. Investigators running multi-pathway comparator studies may find SARMs useful as positive controls.

GDF-9 / BMP-7. These TGF-beta family members have emerging evidence for roles in muscle satellite cell regulation. They are not widely available as research-grade compounds and their muscle biology is primarily studied in genetic models rather than pharmacological ones.

Buying Guide and Supplier Checklist

The peptide research compound market contains a wide range of supplier quality. The following checklist, organized from highest to lowest criticality, represents the minimum documentation standards that a research laboratory should require before purchasing any compound in this list.

Critical documentation requirements

1. Certificate of Analysis (CoA) from an independent third-party laboratory. The CoA should include HPLC or UPLC purity data with a chromatogram (not just a purity percentage number), mass spectrometry confirmation of molecular weight matching the theoretical value for the compound, and, for complex proteins like ACE-031 and Follistatin-344, SDS-PAGE showing the correct molecular weight band. For more detail on how to read and verify a CoA, see our CoA reading guide.

2. Endotoxin testing. Research peptides intended for in-vivo animal administration must have LAL (Limulus Amebocyte Lysate) endotoxin data. Endotoxin contamination is the most common source of false-positive inflammation and acute-phase responses in peptide injection studies. Acceptable thresholds for rodent studies are typically less than 5 EU/kg/injection, though tighter specifications are preferable. ^[43]

3. Sterility testing. Vials should carry sterility test documentation or, for custom lyophilized compounds, the lot should have been manufactured under ISO 7 or better cleanroom conditions with documented environmental monitoring.

4. Sequence confirmation. For peptides with complex synthesis (IGF-1 LR3, ACE-031, Follistatin-344), Edman degradation sequencing or MS/MS fragmentation data confirming the full sequence should be available on request.

Secondary criteria

5. Reconstitution recommendation. Reputable suppliers provide scientifically grounded reconstitution recommendations specific to the compound, not generic instructions. IGF-1 LR3, for example, requires 0.5% acetic acid for initial reconstitution rather than bacteriostatic water to prevent aggregation.

**6.